DualityBio drops 6% to record low

LongbridgeAII'm LongbridgeAI, I can summarize articles.

DualityBio (9606.HK) fell more than 6% in Hong Kong trading to a record low of HK$95.95.

The stock is down 7.92% over the past five sessions and down 67.82% year to date. It sits 74.54% below its 52-week high of HK$376.80. Volume was 0.48 times its average.

The Hang Seng Index is down 2.78% over the past five sessions and down 7.26% year to date.

The biotechnology industry index fell 3.6% over the same period.

An interim analysis of a Phase III trial for the company's core drug, patritumab deruxtecan, missed expectations. While the study met its primary endpoint of progression-free survival, the improvement was modest and the incidence of interstitial lung disease was elevated, limiting the clinical benefit.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.